Author: GLaD

Presentation

Forum explores the complex links between stigma and the law

GLaD

The GLaD program was delighted to be invited to participate in the UNSW Centre for Social Health Research series ‘Spotlight on Stigma’, in April 2022. The ‘Spotlight on Stigma’ series, led by UNSW Professor Carla Treloar, has been running since 2021 and involves a series of forums focussing on stigma, blood-borne viruses and sexually transmitted […]

Research

Drug policy landscapes: Understanding human rights imaginaries and drug policy in Colombia

GLaD

Global discussion about human rights in drug policy reform is increasing. There are several studies that advocate for the need for human rights in drug policy. This advocacy often tends to describe how human rights and drug policy have intersected in the past, or makes a case for reforming drug policy through greater engagement with […]

New article

New research on how human rights processes manage alcohol, other drugs and gender

GLaD

We are excited to announce the publication of the first article from the ARC-funded project, ‘A world-first “post-human rights” framework for drug policy’. Co-authored by GLaD program lead Kate Seear and project officer Sean Mulcahy, the article is titled ‘Enacting safety and omitting gender: Australian human rights scrutiny processes concerning alcohol and other drug laws’. […]

Presentation

Forum hears call for action on drugs, health and human rights

GLaD

Each year, the United Nations celebrates two important, interconnected days on its international calendar. The 10th of December marks International Human Rights Day. In 2021, the theme is ‘Equality’. Two days later, on the 12th of December, the UN will celebrate Universal Health Coverage Day. On this day, we acknowledge the importance of strong, equitable […]

Presentation

The launch of the Global Drug Policy Index

GLaD

GLaD program lead Kate Seear recently joined colleagues from around Australia for a special panel event to mark the launch of the inaugural Global Drug Policy Index. The Index measures and compares national-level drug policies, including their implementation, against the UN’s Common Position on Drugs. The Index assesses and ranks the performance of countries across […]

Presentation

Critical drug scholarship as an otherwise to rights

GLaD

GLaD program lead Kate Seear and project officer Sean Mulcahy recently presented a paper at the After Rights? Politics, Ethics and Aesthetics Workshop.

New article

Stigma-sensitive practice in hepatitis C and HIV testing

GLaD

Earlier in 2021, GLaD program researcher Emily Lenton led an article reporting on this work, titled ‘Upscaling HIV and hepatitis C testing in primary healthcare settings: Stigma-sensitive practice’ in the Australian Journal of Public Health.The article was co-authored with Jen Johnson, previously of the BBV Sector Development Program, and Dr Graham Brown. This article focuses on how healthcare settings can support the goal of upscaling HIV and hepatitis C testing in a way that delivers safe and stigma-free testing encounters.

Submission

Victorian inquiry into cannabis considers law reform

GLaD

A Victorian parliamentary committee recently released a report detailing the findings and recommendations from a major inquiry into the use of cannabis in Victoria. GLaD program lead Associate Professor Kate Seear was one of several people to make a submission to the inquiry.

Research

On International Overdose Awareness Day, new research considers post-mortem rights

GLaD

Each year, on the 31st of August, people around the world come together to mark International Overdose Awareness Day. Initiated in 2001 by Melburnian Sally J Finn, International Overdose Awareness Day is an opportunity to pause, grieve, memorialise lives lost, and to stimulate frank conversations about overdose and other drug-related harms and how to prevent them.

Report

Towards a new Mental Health and Wellbeing Act – considerations for human rights

GLaD

The Royal Commission into Victoria’s Mental Health System delivered its final report in February of this year, and it was tabled in Parliament in March. Among the matters the Commission was appointed to consider was the need to address the stigma associated with mental health, and the need to safeguard human rights.

Research

#HepCantWait, but the legacy effect of stigma and discrimination ‘doesn’t just go away’

GLaD

Since late 2019, COVID-19 has been the global health crisis absorbing much of our attention. Efforts to respond to it, including the redeployment of people and resources, have necessarily had impacts on other public health programs and pandemics. The World Health Organization’s ambitious goal to eliminate hepatitis C by 2030 is one program that has been slowed and, in some places, stopped in its tracks by COVID-19.

News

The New South Wales Mandatory Disease Testing Act

GLaD

The Mandatory Disease Testing Act 2021, recently passed through the New South Wales Parliament,establishes a new scheme under which a person can be ordered to provide a blood sample for the testing of blood-borne viruses if, as a result of their deliberate action, their bodily fluid has come into contact with a health, emergency or public sector worker.

Presentation

Informed consent and upscaling hepatitis C testing – Presentation at the Australasian Viral Hepatitis Conference

GLaD

GLaD team member Emily Lenton recently presented a paper at the 12th Australasian Viral Hepatitis Conference. Her presentation, titled ‘Hepatitis C testing and gaining informed consent: taking stock and innovating for the future’, was co-authored with the convenor of ARCSHS’ Gender, Law and Drugs program, Associate Professor Kate Seear.

Announcement

Post-cure lives – now recruiting

GLaD

Seeking participants for research on people’s lived experience of hepatitis C cure

Part 2 Project update

Life after cure – preliminary findings from the post-cure project

GLaD

What does life look like for people after they have cleared hepatitis C?

Part 1 Project update

Life after cure – preliminary findings from the post-cure project

GLaD

What does life look like for people after they have cleared hepatitis C? Do people whose blood shows no detectable amount of the hepatitis C virus need to inform their doctor or dentist about their previous hepatitis C status? What about prospective employers or insurance providers? Does hepatitis C–related stigma and discrimination remain a challenge for people post-cure? In what ways, and in what settings?

Project update

Hepatitis C cure and ongoing challenges in post-cure lives

GLaD

Australia is spending billions on the universal rollout of direct-acting antiviral drugs (DAAs) as part of its ambitious goal of achieving virtual elimination of hepatitis C by 2030. These ‘revolutionary’, ‘transformative’ drugs can bring about a sustained virological response – that is, a cure – for hepatitis C in over 90 percent of people treated. They are available on the Pharmaceutical Benefits Scheme for all Australians who are covered by Medicare.

Research

Hepatitis C from disability to cure – preliminary findings from ‘speculative legal mapping’

GLaD

As Australia works towards its ambitious target of reducing hepatitis C stigma by 50% by 2022, it is necessary to investigate and understand the issues that continue to affect people who have – and have been treated for – hepatitis C. One significant example of such issues is the set of laws and policies devised in a pre-cure world that have yet to be reformed since the advent of curative treatments. Do people who had hepatitis C need to disclose this to insurers or prospective employers? And could you be refused employment or insurance on such a basis? Does the fact you once had hepatitis C need to be retained in your medical records? There are literally dozens of questions like these to be asked.